4315 studies found for:    gene therapy[ALL-FIELDS]
Show Display Options
Rank Status Study
21 Terminated Gene Therapy for Chronic Granulomatous Disease
Condition: Chronic Granulomatous Disease
Intervention: Drug: Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
22 Completed Gene Therapy for Gyrate Atrophy
Condition: Gyrate Atrophy
Intervention: Procedure: Gene therapy
23 Enrolling by invitation Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy
Conditions: Beta-Thalassemia;   Sickle Cell Disease
Intervention: Other: Safety and efficacy assessments
24 Terminated Suicide Gene Therapy Trial
Condition: Haploidentical Stem Cell Transplantation
Intervention: Biological: HSVTK retrovirally-transduced donor T lymphocytes
25 Active, not recruiting Gene Therapy for Wiskott-Aldrich Syndrome
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with WAS encoding lentiviral vector.
26 Completed Gene Therapy ADA Deficiency
Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
27 Recruiting WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
Conditions: Acute Myeloid Leukaemia;   Chronic Myeloid Leukaemia
Intervention: Genetic: WT1 TCR-transduced T cells
28 Recruiting Gene Therapy for WAS
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
29 Completed Gene Therapy for Alzheimer's Disease Clinical Trial
Condition: Alzheimer Disease
Intervention: Genetic: Human Nerve Growth Factor
30 Recruiting Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Condition: Wiskott-Aldrich Syndrome
Intervention: Genetic: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
31 Active, not recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Other: Gene transfer
32 Completed Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
Condition: Acute Intermittent Porphyria
Interventions: Genetic: rAAV2/5-PBGD vector dosage 1;   Genetic: rAAV2/5-PBGD vector dosage 2;   Genetic: rAAV2/5-PBGD vector dosage 3;   Genetic: rAAV2/5-PBGD vector dosage 4
33 Unknown  Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Genetic: GX-12;   Drug: HAART
34 Recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
35 Recruiting Gene Therapy for Netherton Syndrome
Condition: Netherton Syndrome
Intervention: Genetic: One 20cm2/10cm2 autologous skin sheet graft
36 Recruiting Choroideremia Gene Therapy Clinical Trial
Condition: Choroideremia
Intervention: Genetic: Injection of AAV2-REP1 (10e11 vg)
37 Recruiting A Gene Therapy Study for Hemophilia B
Condition: Hemophilia B
Intervention: Genetic: SPK-9001
38 Not yet recruiting Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury
Condition: Peripheral Nerve Injury
Intervention: Drug: Neovasculgen
39 Enrolling by invitation Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Conditions: Pediatric Cancers;   Hematologic Malignancies;   Solid Tumors
Intervention:
40 Completed Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis
Condition: Retinal Degeneration
Intervention: Biological: tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years